Evidence map›Paper›PMID 24699465›Full record

ArticlePloS one2014

Stem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry.

Ryuji Iida, Robert S Welner, Wanke Zhao, José Alberola-lla, Kay L Medina, Zhizhuang Joe Zhao, Paul W Kincade

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. JAK2Leukemia · 2024
    Article
  2. Article
  3. Similarities Between Stem Cell Niches in Glioblastoma and Bone Marrow: Rays of Hope for Novel Treatment Strategies.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ryuji IidaImmunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Robert S WelnerBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Wanke ZhaoDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
José Alberola-llaImmunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Kay L MedinaDepartment of Immunology, Mayo Clinic, Rochester, Minnesota, United States of America.
Zhizhuang Joe ZhaoDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
Paul W KincadeImmunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · USBeth Israel Deaconess Medical Center · USMayo Clinic · US

Funding

EARLY EVENTS IN MAMMALIAN B-CELL DIFFERENTIATION.R01AI020069 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KINCADE, PAUL WAYNE · 1985 to 2012
$5.2M
Molecular Events Initiating B Cell Fate DeterminationR01HL096108 · NHLBI · MAYO CLINIC ROCHESTER · PI MEDINA, KAY LYNN · 2009 to 2013
$1.9M
Hematopoietic Stem Cell SenescenceR01HL107138 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI ALBEROLA-ILA, JOSE, KINCADE, PAUL WAYNE · 2010 to 2013
$1.6M
Tyrosine Phosphatases PTP-MEG2 and HematopoiesisR01HL079441 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHAO, ZHIZHUANG JOE · 2006 to 2009
$1.4M
EARLY EVENTS IN MAMMALIAN B-CELL DIFFERENTIATIONR37AI020069 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KINCADE, PAUL WAYNE · 1989 to 1996
–
NHLBI NIH HHS HL079441NHLBI NIH HHS HL107138NHLBI NIH HHS R01 HL079441NHLBI NIH HHS R01 HL096108NHLBI NIH HHS R01 HL107138NIAID NIH HHS AI020069NIAID NIH HHS R01 AI020069
6 · The paper itself

Abstract

Although extremely rare, hematopoietic stem cells (HSCs) are divisible into subsets that differ with respect to differentiation potential and cell surface marker expression. For example, we recently found that CD86(-) CD150(+) CD48(-) HSCs have limited potential for lymphocyte production. This could be an important new tool for studying hematological abnormalities. Here, we analyzed HSC subsets with a series of stem cell markers in JAK2V617F transgenic (Tg) mice, where the mutation is sufficient to cause myeloproliferative neoplasia with lymphocyte deficiency. Total numbers of HSC were elevated 3 to 20 fold in bone marrow of JAK2V617F mice. Careful analysis suggested the accumulation involved multiple HSC subsets, but particularly those characterized as CD150(HI) CD86(-) CD18(L)°CD41(+) and excluding Hoechst dye. Real-Time PCR analysis of their HSC revealed that the erythropoiesis associated gene transcripts Gata1, Klf1 and Epor were particularly high. Flow cytometry analyses based on two differentiation schemes for multipotent progenitors (MPP) also suggested alteration by JAK2 signals. The low CD86 on HSC and multipotent progenitors paralleled the large reductions we found in lymphoid progenitors, but the few that were produced functioned normally when sorted and placed in culture. Either of two HSC subsets conferred disease when transplanted. Thus, flow cytometry can be used to observe the influence of abnormal JAK2 signaling on stem and progenitor subsets. Markers that similarly distinguish categories of human HSCs might be very valuable for monitoring such conditions. They could also serve as indicators of HSC fitness and suitability for transplantation.

Indexed as

Signal TransductionAnimalsFlow CytometryJanus Kinase 2MiceMice, TransgenicStem CellsJak2 protein, mouseJanus Kinase 2

Identifiers

PMID24699465
PMCPMC3974768
OpenAlexW1972574634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.